Bristol-Myers Squibb的投资者提升了Bristol-Myers Squibb的股权, 其价值为95.4B美元, Investors boost stakes in Bristol-Myers Squibb, valuing it at $95.4B post strong earnings.

Aurdan资本管理、极地资产管理伙伴和论坛财务管理都增加了对Bristol-Myers Squibb的投资,反映了对该公司的信心。 Aurdan Capital Management, Polar Asset Management Partners, and Forum Financial Management have all increased their investments in Bristol-Myers Squibb, reflecting confidence in the company. Bristol-Myers Squibb最近报告,每股收入为1.8美元,殴打分析师的预期值。 Bristol-Myers Squibb recently reported earnings per share of $1.80, beating analysts' expectations. 该公司价值955.4亿美元,以其在包括Eliquis和Opdivo在内的各种疾病领域的产品闻名。 The company, valued at $95.40 billion, is known for its products in various disease areas, including Eliquis and Opdivo.